Home › Sangamo Announces FDA Clearance Of Investigational New Drug Application
 

Keywords :   


Sangamo Announces FDA Clearance Of Investigational New Drug Application

2016-02-09 03:38:16| drugdiscoveryonline News Articles

Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for SB-318, a single treatment strategy intended to provide a life-long therapy for Mucopolysaccharidosis Type I (MPS I).

Tags: application drug clearance announces

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
16.05Eastern North Pacific Tropical Weather Outlook
16.05Atlantic Tropical Weather Outlook
16.05The man who turned his dead father into a chatbot
16.05Firms leaving UK 'not a crisis' says stock market boss
15.05Exploring the future of agriculture
15.05American, Mexican, and Canadian cattle producers sign joint statement
15.05Attitudes EWG Verified Skincare Line Oceanly Expands with SPF Offerings
15.05Sherwin-Williams Packaging Coatings Expands Non-BPA Coatings Production in Europe
More »